April 4, 2022

The Honorable Shelley Moore Capito  
U.S. Senate  
172 Russell Senate Office Building  
Washington, DC 20150

The Honorable Jeanne Shaheen  
U.S. Senate  
506 Hart Senate Office Building  
Washington, DC 20510

The Honorable Mike Thompson  
U.S. House of Representatives  
268 Cannon House Office Building  
Washington, DC 20515

The Honorable David B. McKinley, P.E.  
U.S. House of Representatives  
2239 Rayburn House Office Building  
Washington, DC 20515

Re: S. 3791/H.R. 7051 – Access to Prescription Digital Therapeutics Act of 2022

Dear Senator Moore Capito, Senator Shaheen, Representative Thompson, and Representative McKinley:

The Academy of Managed Care Pharmacy (AMCP) thanks you for your leadership on and introduction of the bipartisan, bicameral Access to Prescription Digital Therapeutics Act of 2022 (S. 3791/H.R. 7051). This bill to authorize coverage of prescription digital therapeutics (PDTs), which are software-based disease treatments, by the Medicare and Medicaid programs, which serve some of the most vulnerable members of our society, is one of AMCP's top priorities and is essential to getting patients the medications they need at a cost they can afford.

AMCP is the nation's leading professional association dedicated to increasing patient access to affordable medicines, improving health outcomes, and ensuring the wise use of health care dollars. Through evidence and value-based strategies and practices, AMCP's diverse membership of pharmacists, physicians, nurses, biopharmaceutical professionals, and other stakeholders leverage their specialized expertise in clinical evidence and economics to optimize medication benefit design and population health management and help patients access cost-effective and safe medications and other drug therapies. AMCP members improve the lives of nearly 300 million Americans served by private and public health plans, pharmacy benefit management firms, government health programs, and emerging care models.

Because PDTs are tested for safety and efficacy in randomized clinical trials, evaluated by the Food & Drug Administration, and prescribed by healthcare providers, they are effective at treating some of the most devastating diseases, such as substance and opioid use disorders, mental and behavioral health issues, and Parkinson's disease.

The current public health emergency and COVID-19 pandemic have demonstrated to Americans just how vital innovation and technology are to increasing patient access and the quality of health care by
bridging significant care gaps created by shortages of specialty providers and geographic obstacles. The *Access to Prescription Digital Therapeutics Act* ensures that effective treatments like PDTs are more broadly available to patients in need, particularly our seniors. By establishing a prescription digital therapeutics benefit category within Medicare and Medicaid, these evidence-based remote treatment modalities will be available to the patients within both programs who need them most.

On behalf of AMCP, I thank you for your leadership and strongly encourage other Members of Congress to co-sponsor and pass this important bipartisan legislation that will improve access to care for millions of Americans.

Sincerely,

Susan A. Cantrell, MHL, RPh, CAE
Chief Executive Officer